RYE, N.Y., May 19 Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, has introduced a redesigned logo and launched a new Web site, the company announced.
(Logo: http://www.newscom.com/cgi-bin/prnh/20100519/NY06814LOGO )
Curemark's new logo, which features a white constellation design on a dark blue background, was created by Unit7 (www.unit7.com), an Omnicom company. Benchworks (www.benchworks.com), a marketing and branding services firm, created the new design for Curemark's Web site.
"Our new logo and Web site better reflect Curemark's mission and momentum as we continue to develop our drug pipeline and look to create scientific innovations that turn hope into reality," said Dr. Joan Fallon, founder and CEO.
"We believe that the logo's 'constellation' design helps communicate a sense of wonder and possibility which we hope to bring through research to the service of humanity. We intend it to be a mark of trust," Fallon said. "The redesigned Web site complements our new logo with a cleaner look and as an important information source on the company, it is intended to communicate our purpose more clearly."
Curemark is currently in Phase III clinical trials for CM-AT, an autism treatment that will be one of the first to address the underlying physiology of autism. CM-AT, granted Fast Track status by the FDA, is based on Fallon's research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein. The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function.
The company plans to initiate additional clinical programs for other neurological disorders including ADHD and Parkinson's disease in the near future, Fallon said.
About CUREMARK LLC
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com.
Safe Harbor Statement
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.
Contact: Michelle Manoff Rubenstein Public Relations 212-843-8051 email@example.com
SOURCE Curemark, LLC